Cargando…

Creation of a Novel Inflammation-Based Score for Operable Colorectal Cancer Patients

AIM: Systemic inflammation has been implicated in the progression of patients with colorectal cancer (CRC). We evaluated the prognostic ability of a comprehensive score based on several inflammatory indexes in operable CRC patients. PATIENTS AND METHODS: Between July 2013 and September 2017, this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Qian, Cao, Yinghao, Wang, Shouyi, Zhu, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547789/
https://www.ncbi.nlm.nih.gov/pubmed/33116746
http://dx.doi.org/10.2147/JIR.S271541
_version_ 1783592494499364864
author Huang, Qian
Cao, Yinghao
Wang, Shouyi
Zhu, Rui
author_facet Huang, Qian
Cao, Yinghao
Wang, Shouyi
Zhu, Rui
author_sort Huang, Qian
collection PubMed
description AIM: Systemic inflammation has been implicated in the progression of patients with colorectal cancer (CRC). We evaluated the prognostic ability of a comprehensive score based on several inflammatory indexes in operable CRC patients. PATIENTS AND METHODS: Between July 2013 and September 2017, this study retrospectively identified 1279 CRC patients receiving radical surgery in Wuhan Union Hospital and randomly assigned them into training (N=921) and validation (N=358) sets. A novel score, the CRC-specific inflammatory index (CSII), was developed from a series of inflammatory indexes significantly associated with survival in patients with CRC. This novel score was then divided into three categories and compared to the well-known systematic inflammatory index (SII) and TNM stage. Finally, a survival nomogram was generated by combining the CSII and other informative clinical features. RESULTS: The CSII-OS was calculated as 1.110×lg ALRI + 1.082×CAR + 0.792×PI, while CSII-DFS was 1.709×lg ALRI + 1.033×CAR based on multivariable Cox regression analysis. Patients with high CSII experienced a worse OS (HR=23.72, 95% CI, 11.30–49.78, P <0.001) and worse DFS (HR=15.62, 95% CI, 6.95–35.08, P <0.001) compared to those in CRC patients with low CSII. Moreover, ROC analyses showed that the CSII possessed excellent performance (AUC=0.859) in predicting OS and DFS. The AUC of the OS nomogram based on CSII, TNM stage, and chemotherapy was 0.897, while that of the DFS nomogram based on CSII, T stage, and TNM stage was 0.873. High-quality calibration curves in both OS and DFS nomograms were observed. Verification in the validation dataset showed results consistent with those in the training dataset. CONCLUSION: The CSII is a CRC-specific prognostic score based on the combination of available inflammatory indexes. High CSII is a strong predictor of worse survival outcomes. The CSII also exhibits better predictive performance compared to SII or TNM stage in operable CRC patients.
format Online
Article
Text
id pubmed-7547789
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75477892020-10-27 Creation of a Novel Inflammation-Based Score for Operable Colorectal Cancer Patients Huang, Qian Cao, Yinghao Wang, Shouyi Zhu, Rui J Inflamm Res Original Research AIM: Systemic inflammation has been implicated in the progression of patients with colorectal cancer (CRC). We evaluated the prognostic ability of a comprehensive score based on several inflammatory indexes in operable CRC patients. PATIENTS AND METHODS: Between July 2013 and September 2017, this study retrospectively identified 1279 CRC patients receiving radical surgery in Wuhan Union Hospital and randomly assigned them into training (N=921) and validation (N=358) sets. A novel score, the CRC-specific inflammatory index (CSII), was developed from a series of inflammatory indexes significantly associated with survival in patients with CRC. This novel score was then divided into three categories and compared to the well-known systematic inflammatory index (SII) and TNM stage. Finally, a survival nomogram was generated by combining the CSII and other informative clinical features. RESULTS: The CSII-OS was calculated as 1.110×lg ALRI + 1.082×CAR + 0.792×PI, while CSII-DFS was 1.709×lg ALRI + 1.033×CAR based on multivariable Cox regression analysis. Patients with high CSII experienced a worse OS (HR=23.72, 95% CI, 11.30–49.78, P <0.001) and worse DFS (HR=15.62, 95% CI, 6.95–35.08, P <0.001) compared to those in CRC patients with low CSII. Moreover, ROC analyses showed that the CSII possessed excellent performance (AUC=0.859) in predicting OS and DFS. The AUC of the OS nomogram based on CSII, TNM stage, and chemotherapy was 0.897, while that of the DFS nomogram based on CSII, T stage, and TNM stage was 0.873. High-quality calibration curves in both OS and DFS nomograms were observed. Verification in the validation dataset showed results consistent with those in the training dataset. CONCLUSION: The CSII is a CRC-specific prognostic score based on the combination of available inflammatory indexes. High CSII is a strong predictor of worse survival outcomes. The CSII also exhibits better predictive performance compared to SII or TNM stage in operable CRC patients. Dove 2020-10-06 /pmc/articles/PMC7547789/ /pubmed/33116746 http://dx.doi.org/10.2147/JIR.S271541 Text en © 2020 Huang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Huang, Qian
Cao, Yinghao
Wang, Shouyi
Zhu, Rui
Creation of a Novel Inflammation-Based Score for Operable Colorectal Cancer Patients
title Creation of a Novel Inflammation-Based Score for Operable Colorectal Cancer Patients
title_full Creation of a Novel Inflammation-Based Score for Operable Colorectal Cancer Patients
title_fullStr Creation of a Novel Inflammation-Based Score for Operable Colorectal Cancer Patients
title_full_unstemmed Creation of a Novel Inflammation-Based Score for Operable Colorectal Cancer Patients
title_short Creation of a Novel Inflammation-Based Score for Operable Colorectal Cancer Patients
title_sort creation of a novel inflammation-based score for operable colorectal cancer patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547789/
https://www.ncbi.nlm.nih.gov/pubmed/33116746
http://dx.doi.org/10.2147/JIR.S271541
work_keys_str_mv AT huangqian creationofanovelinflammationbasedscoreforoperablecolorectalcancerpatients
AT caoyinghao creationofanovelinflammationbasedscoreforoperablecolorectalcancerpatients
AT wangshouyi creationofanovelinflammationbasedscoreforoperablecolorectalcancerpatients
AT zhurui creationofanovelinflammationbasedscoreforoperablecolorectalcancerpatients